Concepedia

Deepthi Bhupathi

DB

8

Publications

367

Citations

8

H-Index

2011

Active since

Affiliations

Threshold Pharmaceuticals (United States)(Current)

Deepthi Bhupathi is an author at Threshold Pharmaceuticals (United States) specializing in medicine, cancer research, and pharmacology.

Top concepts

Publications per year

2011–2023

8

Publications

8

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

Fanying Meng, James Evans, Deepthi Bhupathi et al. · Molecular Cancer Therapeutics · 2011 · 203 citations

, , +18

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia et al. · Cancer Biology & Therapy · 2015 · 51 citations · Full text

, , +15

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

Jessica D. Sun, Dharmendra Ahluwalia, Qian Liu et al. · PubMed · 2015 · 26 citations · Full text

, , +17

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

Fanying Meng, Deepthi Bhupathi, Jessica D. Sun et al. · BMC Cancer · 2015 · 24 citations · Full text

14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment

Jianxin Duan, Xiaohong Cai, Fanying Meng et al. · Journal of Medicinal Chemistry · 2011 · 21 citations

, , +16

Rows per page

1–5 of 8